The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix. The company's stock fell around 27% over the past five days and has a 52-week low of $58.93 </em></a>.
RSI Value: 24.03
EW Price Action: Shares of Edwards Lifesciences fell 0.2% to close at $63.64 on Tuesday.
On July 25, DexCom reported worse-than-expected second-quarter revenue results and issued weak revenue guidance. "While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Dexcom's CEO. "We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth." The company's stock fell around 38% over the past five days. It has a 52-week low of $62.34.
RSI Value: 20.25
DXCM Price Action: Shares of DexCom gained 3.3% to close at $69.70 on Tuesday.
On July 29, BiomX announced NYSE American acceptance of plan to regain listing compliance. The company's stock dipped around 43% over the past month and has a 52-week low of $0.19.</em></a>
RSI Value: 24.28
PHGE Price Action: Shares of Biomx fell 8.5% to close at $0.19 on Tuesday.
